Sibrotuzumab, a humanized anti-FAP monoclonal antibody, inhibited the dipeptidyl peptidase activity of FAP but did not show efficacy in suppressing pancreatic cancer growth in patients, despite the radiolabeled version of the antibody accumulating in tumors as visualized by SPECT (213, 214). Here, FAP is linked to pancreatic neoplasm.